Katy Wack is the Vice President of Clinical Development and Regulatory affairs, joining the PathAI team in November of 2019. In addition to leading all clinical and regulatory strategy, she designed and led PathAI’s Clinical Trial Services Program and spearheaded the AIM- NASH Drug Development Tool qualification effort. She brings clinical and scientific expertise through her decade of work in drug development and digital pathology. Previous to PathAI, she served as Vice President of Development for an oncolytic virus company in co-development with Pfizer, leading IND-enabling preclinical, assay and process development, and CMC activities. Prior to that, Katy served as Lead Clinical Scientist at a digital pathology company, where she led a 4-site PMA clinical study for primary diagnosis, publishing and patenting novel analytical methodologies. Katy earned her B.S. in Biological Science and Engineering from Carnegie Mellon, her M.S. in Liver Tissue Engineering and Toxicology from M.I.T., and her PhD from University of Pittsburgh in Cell Biology and Pathology, using quantitative imaging to study age-related chronic kidney disease.